scholarly journals The effects of exercise and social support on mothers reporting depressive symptoms: A pilot randomized controlled trial

2003 ◽  
Vol 12 (2) ◽  
pp. 130-138 ◽  
Author(s):  
Kylie Armstrong ◽  
Helen Edwards
2017 ◽  
Vol 73 (10) ◽  
pp. 1226-1246 ◽  
Author(s):  
Carrie Pettus-Davis ◽  
Allison Dunnigan ◽  
Christopher A. Veeh ◽  
Matthew Owen Howard ◽  
Anna M. Scheyett ◽  
...  

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Martin Nikolaus Dichter ◽  
Bernd Albers ◽  
Diana Trutschel ◽  
Armin Michael Ströbel ◽  
Swantje Seismann-Petersen ◽  
...  

2018 ◽  
Vol 6 (4) ◽  
pp. 311-320 ◽  
Author(s):  
Kathrin Milbury ◽  
Jing Li ◽  
Shiao-Pei Weathers ◽  
Smitha Mallaiah ◽  
Terri Armstrong ◽  
...  

Abstract Background While the use of behavioral medicine in managing glioma patients’ symptoms is not well studied, the high symptom burden in patients and their family caregivers is well established. We conducted a pilot randomized, controlled trial to examine the feasibility and preliminary efficacy of a dyadic yoga (DY) intervention as a supportive care strategy. Methods Glioma patients undergoing radiotherapy and their caregivers were randomized to a 12-session DY or waitlist control (WLC) group. Prior to radiotherapy and randomization, both groups completed measures of cancer-related symptoms (MD Anderson Symptom Inventory-Brain Tumor module), depressive symptoms (Center for Epidemiological Studies-Depression measure), fatigue (Brief Fatigue Inventory), and overall quality of life (QOL; Medical Outcomes Study 36-item short-form survey). Dyads were reassessed at the last day of radiotherapy. Results Twenty patients (mean age: 46 years, 50% female, 80% WHO grade IV and caregivers (mean age: 50 years, 70% female, 50% spouses) participated in the trial. A priori feasibility criteria were met regarding consent (70%), adherence (88%), and retention (95%) rates. Controlling for relevant covariates, change score analyses revealed clinically significant improvements for patients in the DY compared with the WLC group for overall cancer symptom severity (d = 0.96) and symptom interference (d = 0.74), depressive symptoms (d = 0.71), and mental QOL (d = 0.69). Caregivers in the DY group reported clinically significant improvements in depressive symptoms (d = 1.12), fatigue (d = 0.89), and mental QOL (d = 0.49) relative to those in the WLC group. Conclusion A DY intervention appears to be a feasible and beneficial symptom and QOL management strategy for glioma patients undergoing radiotherapy and their caregivers. An efficacy trial with a more stringent control group is warranted. Clinical Trial Number NCT02481349


2020 ◽  
Author(s):  
Emma Bruehlman-Senecal ◽  
Cayce J Hook ◽  
Jennifer H Pfeifer ◽  
Caroline FitzGerald ◽  
Brittany Davis ◽  
...  

BACKGROUND Loneliness is a widespread and significant problem on college campuses. Prolonged loneliness in young adulthood is a risk factor for concurrent and future mental health problems and attrition, making college a critical time for support. Cognitive and behavioral interventions show promise for decreasing loneliness and can be widely disseminated through technology. OBJECTIVE This pilot randomized controlled trial was conducted to examine the initial efficacy, feasibility, and desirability of a smartphone app, Nod, designed to deliver cognitive and behavioral skill-building exercises to reduce loneliness during the transition to college. METHODS First-year college students (N=221, mean age 18.7 years, 59% female) were recruited online during incoming student orientation, and randomized to either receive immediate access to Nod (experimental group, n=100) or access after 4 weeks (control group, n=121). The app delivered skills via fully automated (1) “social challenges,” suggested activities designed to build social connections; (2) reflections, brief cognitive reframing exercises; and (3) student testimonials that encouraged a growth mindset toward social connection building. Main intention-to-treat analyses were used to compare the conditions on self-assessed loneliness, depressive symptoms, and other mental health and college adjustment outcomes at week 4, controlling for baseline values on those variables. Analyses were also performed to test the hypothesis that the treatment benefits would be particularly pronounced for participants with heightened psychological vulnerability at baseline (ie, higher baseline depressive symptoms and loneliness). RESULTS Retention was 97% at week 4, and participants viewed an average 36.7 pages of app content. There were no significant condition differences in loneliness at week 4 (<i>F</i><sub>1, 211</sub>=0.05, <i>P=</i>.82; η<sub>p</sub><sup>2</sup> &lt;.001). However, there was a significant condition-by-baseline depression interaction to predict week-4 loneliness (<i>F</i><sub>1,209</sub>=9.65, <i>P=</i>.002; η<sub>p</sub><sup>2</sup> =.04). Simple slope analyses indicated that baseline depression positively predicted week-4 loneliness among control participants (<i>r</i>=0.30, t<sub>209</sub>=3.81, <i>P</i>&lt;.001), but not among experimental participants (<i>r</i>=–0.09, t<sub>209</sub>=–0.84, <i>P</i>=.40), suggesting that Nod buffered participants with high baseline depression scores from experiencing heightened midquarter loneliness. Similarly, there were no significant condition differences in other week-4 outcomes. However, moderation by baseline vulnerability was found for week-4 depressive symptoms, sleep quality, and indices of college adjustment (eg, perceived social support and campus belonging). CONCLUSIONS Although Nod exposure did not impact outcomes for the full sample, these results provide initial evidence of its benefit for vulnerable students. The results of this trial suggest that cognitive and behavioral skills delivered via a mobile app can buffer psychologically vulnerable college students against heightened loneliness and depressive symptoms, as well as other negative college adjustment outcomes. Future work will aim to improve upon app engagement, and to address loneliness among other key populations. CLINICALTRIAL ClinicalTrials.gov NCT04164654; https://clinicaltrials.gov/ct2/show/NCT04164654


Sign in / Sign up

Export Citation Format

Share Document